U.S. stock night market volatility: Galecto fell 4.49% in after-hours trading, with acquisition news and technical signals raising market concerns

U.S. Stock Night Market Movements

Galecto fell 4.49% in the night market. Based on recent news,

1. On November 10, Galecto announced the acquisition of Damora and simultaneously conducted an oversubscribed $285 million private investment to advance its potential best treatment options for improving outcomes in patients with myeloproliferative tumors. However, the market reacted poorly to this news, leading to a decline in stock price.

2. On November 10, technical sentiment signals indicated a sell-off, with a current market capitalization of $6.57 million. Negative signals from technical indicators further exacerbated investors' selling sentiment, resulting in a drop in stock price.

3. On November 11, analysts warned investors to exercise caution with Galecto and Movano stocks. Although these stocks surged significantly that day, there may be traps. This warning raised market concerns, leading to a decline in stock price. Recently, the market has seen high volatility in small-cap stocks, and investors should be cautious.

Stocks with High Trading Volume in the Industry

BeiGene rose 0.86% in the night market. Based on recent key news:

1. On November 12, BeiGene released its performance for the first three quarters of 2025, with revenue increasing by 44.2% year-on-year and net profit turning from loss to profit, driving the stock price up by 7.7%. Investment banks mainly rated it as a buy, with the target price raised to HKD 237. Source: Zhitong Finance

2. On November 12, BeiGene recorded significant cross-trade transactions, with the stock price 7.9% higher than the previous day's closing price, and a net active buying of HKD 186 million, indicating strong market demand for its stock. Source: Economic Information Agency

3. On November 11, Haitong International raised BeiGene's revenue and net profit expectations, reflecting better-than-expected sales growth in the U.S. and European markets, maintaining an "outperform" rating. Source: Zhitong Finance. The biopharmaceutical industry is performing strongly, with significant capital inflows.

Korro Bio fell 76.77% in the night market. Based on recent key news:

1. On November 13, Korro Bio announced a one-year suspension of its research and licensing agreement with Novo Nordisk and will incur approximately $2.4 million in restructuring costs. This move raised market concerns about the company's future collaborations and financial status, leading to a significant drop in stock price. Source: MarketWatch

2. On November 13, the company's quarterly earnings and revenue exceeded and fell short of expectations, respectively, with earnings exceeding by 26.44%, but revenue falling short by 27.33%. This inconsistent financial performance heightened investor anxiety, further driving down the stock price. Source: MarketWatch

3. On November 13, Korro Bio reported total cash, cash equivalents, and marketable securities of $102.5 million as of September 30, 2025, supporting operations until the second half of 2027. Despite a solid financial position, the market lacks confidence in its long-term development strategy, affecting stock performance. Source: Public Technologies. The biopharmaceutical industry faces policy and market uncertainties Recursion rose 0.65% in after-hours trading. Based on recent key news:

4. On November 10, Recursion Pharmaceuticals participated in an investor conference, but the lack of short-term catalysts led to stock price volatility. Despite insider buying, analysts were overly optimistic about its target price, resulting in a poor market reaction with a trading volume of $93,700;

5. On November 9, AbCellera Biologics saw its stock price drop by 29.5% due to analysts downgrading their ratings and weak financial metrics. Concerns over its growth trajectory and operational efficiency intensified, leading to weakened market confidence;

6. On November 8, the overall market performance was weak, with portfolio performance declining by 22.7%, affecting the price trends of related stocks. The overall market performance was weak, with significant capital outflows